Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices.
Indexed inpubmed
Abstract
During its February 2015 meeting, the Advisory Committee on Immunization Practices (ACIP) recommended 9-valent human papillomavirus (HPV) vaccine (9vHPV) (Gardasil 9, Merck and Co., Inc.) as one of three HPV vaccines that can be used for routine vaccination. HPV vaccine is recommended for routine vaccination at age 11 or 12 years. ACIP also recommends vaccination for females aged 13 through 26 years and males aged 13 through 21 years not vaccinated previously. Vaccination is also recommended through age 26 years for men who have sex with men and for immunocompromised persons (including those with HIV infection) if not vaccinated previously. 9vHPV is a noninfectious, virus-like particle (VLP) vaccine. Similar…
Citation impact
1,061
total citations
- FWCI
- 106.78
- Percentile
- 100%
- References
- 12
Citations per year
Authors
9Topics & keywords
Keywords
- Medicine
- Vaccination
- Immunization
- Virus-like particle
- Human papillomavirus
- Pediatrics
- Immunology
- Internal medicine
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.